Drug intelligence / Profile preview

Fuzheng Qingying

Development stage: Unknown
Lead developer: Longhua Hospital Shanghai University of Traditional Chinese Medicine
Administration: Oral

Overview

Fuzheng Qingying is a Traditional Chinese Medicine (TCM) formulation currently undergoing clinical investigation for the treatment of Hashimoto's thyroiditis. It is administered in a granular form, suggesting oral administration. The drug is being developed by institutions such as Longhua Hospital, Shanghai University of Traditional Chinese Medicine, and Shanghai Key Clinical Specialty (Surgery).

Other names: Fuzheng Qingying prescriptionFuzhengqingying granules扶正清瘿颗粒扶正清瘿中药

Beyond the preview

Go deeper on Fuzheng Qingying.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuzheng Qingying.

Explore the full profile